Ligand Pharmaceuticals (LGND) Cash & Equivalents Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 47.78% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn | 9.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.05% |
| Dec 31, 2025 | 57.23% |
| Sep 30, 2025 | 223.52% |
| Jun 30, 2025 | 134.02% |
| Mar 31, 2025 | 47.37% |
| Dec 31, 2024 | 54.72% |
| Sep 30, 2024 | 39.51% |
| Jun 30, 2024 | -6.03% |
| Mar 31, 2024 | 16.29% |
| Dec 31, 2023 | -21.59% |
| Sep 30, 2023 | -65.19% |
| Jun 30, 2023 | -37.26% |
| Mar 31, 2023 | -8.94% |
| Dec 31, 2022 | -14.32% |
| Sep 30, 2022 | -73.66% |
| Jun 30, 2022 | -73.16% |
| Mar 31, 2022 | -47.75% |
| Dec 31, 2021 | -44.97% |
| Sep 30, 2021 | -41.25% |
| Jun 30, 2021 | -47.54% |